Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO News In Brief: Allergan Ligand Retinoid Therapeutics ALRT1057

Executive Summary

Allergan Ligand Retinoid Therapeutics ALRT1057: Interim findings of Phase I/II Memorial Sloan-Kettering Cancer Center trial of 9-cis retinoic acid capsules used in the treatment of 15 acute promyelocytic leukemia patients results in 40% complete remission rate for durations of two to 18 months. Unlike ALRT1057, all-trans retinoic acid maintenance therapy for APL often results in retinoid resistance within a few months of treatment, the company said. Irvine, Calif.-based ALRT will begin Phase II/III with ALRT1057 trials this year...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel